Prediction Case File
YouTubeEvaluation Complete

Arcus Biosciences Inc. Stock Prediction and Forecast [RCUS]

1 extracted signal · 1 resolved · 0 still active

StockInvest.us profile imageStockInvest.usIndependent analyst profile
Source published
25 Nov 2025, 04:45 UTC
Recorded by Tahlil Plus
18 May 2026, 20:23 UTC
Video preview for Arcus Biosciences Inc. Stock Prediction and Forecast [RCUS]
Source overview

AI-generated source summary

Arqus Biosciences Inc. (RCUS) stock exhibits a strong rising trend with positive signals from both short and long-term moving averages. The stock is currently trading at $23.18, indicating it is overvalued. Analysts have assigned it a 'Strong Buy Candidate' rating with a target price of $30.311 and a stop-loss set at $22.39 (-3.40%). The stock has shown medium daily movements, contributing to a medium risk profile. The RSI is at 80, further increasing risk. A buy signal was identified from a pivot bottom 11 days ago, and the stock has since risen 20.04% with increasing volume. In the short term, a potential dip to the support level of $20.35 is anticipated, with further gains expected in the next three months. However, breaches below $20.99 and $18.61 would indicate sell signals. Longer-term, the stock is projected to increase by 43.74% to $33.18. The P/E ratio is -7.07, suggesting potential for bankruptcy. Insider trading data shows a net sell-off, with a significant insider power score of 82.637, indicating substantial insider buying over the last 100 transactions.

AI-generated summary based on the source content.

Live evaluation

Signal outcomes at a glance

Evaluation Complete
Signals
1
Extracted from this source
Open
0
Still being tracked
Successful
0
Resolved successfully
Failed
1
Resolved unsuccessfully
Other
0
Cancelled, invalid or excluded
Resolved success
0%
1 resolved; open signals omitted
Extracted intelligence

Signals in this source

Case timeline

Evidence and evaluation progress

  1. Original source published

    The analyst published the original source item.

  2. Source recorded by Tahlil Plus

    The public source was preserved as the evidence record for this case.

  3. Market predictions extracted

    1 eligible signal linked to this case.

  4. Outcome tracking started

    Tahlil Plus began monitoring the extracted predictions.

  5. First prediction resolved

    The first evaluable outcome in this case reached a terminal result.

  6. Case evaluation completed

    All evaluable predictions in this case reached terminal outcomes.

Analyst snapshot

StockInvest.us

Platform-wide history, separate from this source evaluation.

Reliability
53.4
Tracked signals
1779
Historical success
42.8%
View full analyst profile →
Methodology & disclosure

Tahlil Plus independently records and evaluates public market predictions. Extraction may be AI-assisted and results follow the Tahlil Plus methodology. This information is not financial advice.

Continue the evidence trail